A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumorsPATNAIK, Amita; LORUSSO, Patricia M; DARBONNE, Walter C et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 5, pp 951-960, issn 0344-5704, 10 p.Article

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumorsTOLCHER, Anthony W; RODRIGUEZA, Wendi V; WOOLLISCROFT, Michael J et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 2, pp 363-371, issn 0344-5704, 9 p.Article

A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumorsMOSTAFA, Nael M; CHIU, Yi-Lin; ROSEN, Lee S et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 3, pp 583-591, issn 0344-5704, 9 p.Article

A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasmsFIGG, William D; MONGA, Manish; RYAN, Qin C et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 5, pp 955-967, issn 0344-5704, 13 p.Article

A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignanciesYANG BRUCE, Justine; KOLESAR, Jill M; JERAJ, Robert et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 3, pp 485-493, issn 0344-5704, 9 p.Article

A phase I study of oral ixabepilone in patients with advanced solid tumorsDEEKEN, John F; MARSHALL, John L; PISHVAIAN, Michael J et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 5, pp 1071-1078, issn 0344-5704, 8 p.Article

A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancerEGUCHI, Hidetoshi; NAGANO, Hiroaki; KUDO, Toshihiro et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 2, pp 309-315, issn 0344-5704, 7 p.Article

A phase II study of metronomic paclitaxel/cyclophosphamide/ capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancerMASUDA, N; HIGAKI, K; MORITA, S et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 2, pp 229-238, issn 0344-5704, 10 p.Article

A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001)HATTORI, Yoshihiro; SATOUCHI, Miyako; MORITA, Satoshi et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 1, pp 17-23, issn 0344-5704, 7 p.Article

A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancerHEE KYUNG AHN; MINKYU JUNG; SUN JIN SYM et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 2, pp 277-282, issn 0344-5704, 6 p.Article

A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancerHYUN CHANG; SUNG KWAN SHIN; HYE RYUN KIM et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 4, pp 665-671, issn 0344-5704, 7 p.Article

An evaluation of the potential for drug―drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphomaDARWISH, Mona; BURKE, John M; HELLRIEGEL, Edward et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 6, pp 1119-1127, issn 0344-5704, 9 p.Article

Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patientsHAN, Fei-Fei; GUO, Chang-Long; DAN YU et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 4, pp 779-788, issn 0344-5704, 10 p.Article

Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II studyYULONG ZHENG; WEIJIA FANG; CHENYU MAO et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 3, pp 503-509, issn 0344-5704, 7 p.Article

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancerVIJAYVERGIA, Namrata; MEHRA, Ranee.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 3, pp 437-446, issn 0344-5704, 10 p.Article

Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. coli L-asparaginase preparation (MC0609) in Beagle dogBORGHORST, Stephan; HEMPEL, Georg; POPPENBORG, Sabine et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 2, pp 367-378, issn 0344-5704, 12 p.Article

Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx^®)BOERS-SONDEREN, Marye J; VAN HERPEN, Carla M. L; VAN DER GRAAF, Winette T. A et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 3, pp 457-463, issn 0344-5704, 7 p.Article

Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use programLEE, Jae-Lyun; SE HOON PARK; KOH, Su-Jin et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 5, pp 1005-1013, issn 0344-5704, 9 p.Article

Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cellsROY, Sudipa S; KIRMA, Nameer B; SANTHAMMA, Bindu et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 6, pp 1263-1271, issn 0344-5704, 9 p.Article

Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myelomaTHOMAS, Sheeba K; SUVOROV, Alexander; MING QI et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 1, pp 35-42, issn 0344-5704, 8 p.Article

Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteersSHAIK, M. Naveed; LABADIE, Robert R; RUDIN, Dan et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 2, pp 411-418, issn 0344-5704, 8 p.Article

Expression of a novel peptide derived from PCNA damages DNA and reverses cisplatin resistanceLINGEMAN, Robert G; HICKEY, Robert J; MALKAS, Linda H et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 5, pp 981-993, issn 0344-5704, 13 p.Article

First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancerMUHAMMAD WASIF SAIF; JIA LI; LAMB, Lynne et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 2, pp 373-380, issn 0344-5704, 8 p.Article

Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancerJUN CAO; JIAN ZHANG; ZHONGHUA WANG et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 2, pp 389-398, issn 0344-5704, 10 p.Article

Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapyKANEKAWA, Takenori; NAGAI, Hidenari; KANAYAMA, Masahiro et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 5, pp 899-909, issn 0344-5704, 11 p.Article